Search PubMed⌕ Search

Biomedical subjects

S Hashimoto

Publications and source records attributed to S Hashimoto.

At least 1,243 records · Page 69Linked to original sources
PubMed1984

[Quantitation of mitral regurgitation by left ventricular blood flow dynamics: a pulsed Doppler echocardiographic study].

Using pulsed Doppler echocardiography, the blood flow dynamics in the left ventricular cavity were studied in 52 cases with mitral regurgitation (MR) (32 cases of grade 1 or 2 and 20 cases of grade 3 or 4 according to the Sellers' classification) were studied to quantify the severity of MR. Twelve healthy subjects served as the control. The results were as follows: At the mitral orifice, systolic laminar flow toward the left atrial cavity was observed in 17 cases with grade 3 or 4 MR. This flow was shown to begin at the isovolumic contraction phase and it had a higher velocity in end-systole. Thus, it could easily be differentiated from ejection flow observed in the left ventricular outflow tract. The duration of systolic blood flow in the mid-ventricle was significantly prolonged over that in the outflow tract in cases with grade 3 or 4 MR compared to those with grade 1 or 2 MR (grade 1 or 2: 4 +/- 27 msec, grade 3 or 4: 65 +/- 35 msec, p less than 0.001), indicating that MR continued even after the end of left ventricular ejection. The velocity of early diastolic left ventricular inflow was estimated for cases having isolated MR (16 cases with mitral chordal rupture and one case of mitral valve prolapse syndrome). In the healthy subjects and cases with grade 1 or 2 MR, the velocity was less than 84 cm/sec. The velocity was increased more than 100 cm/sec in grade 3 or 4 MR. These observations indicated the clinical potential of abnormal blood flow dynamics in the left ventricular cavity in the semi-quantification of MR.

Blood Flow Velocity↗
PubMed1984

A new orally active hypotensive peptide, N-(dibenzyloxyphosphinoyl)-L-alanyl-L-prolyl-L-proline (PAPP).

The antihypertensive effects and mechanisms of a newly developed orally active tripeptide, N-(dibenzyloxyphosphinoyl)-L-alanyl-L-prolyl-L-proline (PAPP), were investigated. When PAPP (1-30 mg/kg orally) was administered to spontaneously hypertensive rats (SHR), systolic blood pressure (SBP) reached a maximum reduction after 8 h and this effect lasted over 24 h. In two-kidney, one clip hypertensive rats (2KIC rats) and DOCA-salt hypertensive rats, PAPP also reduced SBP. In normotensive Wistar rats, however, PAPP did not have a hypotensive effect. PAPP showed low toxicity in Sprague-Dawley rats. The depressor response to bradykinin (BK) was potentiated, but the pressor response to angiotensin I (ANG I) was not inhibited by PAPP. PAPP significantly relaxed isolated SHR aortic strips treated with KC or norepinephrine. Angiotensin converting enzyme (ACE) inhibition by PAPP was relatively low in vivo and in vitro.

Administration, Oral↗
PubMed1984

[The analgesic and antipyretic effects of a non-steroidal anti-inflammatory drug, oxaprozin, in experimental animals].

The analgesic and antipyretic effects of oxaprozin were investigated in comparison with those of indomethacin, ibuprofen, phenylbutazone and aspirin. On the various writhing tests in mice, the analgesic effect of oxaprozin was about 2 to 9 times more potent than those of ibuprofen, phenylbutazone and aspirin. On the other hand, the analgesic and antipyretic effects of oxaprozin in rats were roughly equivalent to those of aspirin, but less effective than those of the other drugs tested. On the urate synovitis test in dogs, only oxaprozin showed a prophylactic effect. Therefore, The effect of oxaprozin in mice and dogs was more potent than ibuprofen, phenylbutazone and aspirin. The metabolic rate of oxaprozin in rats is 3.5 and 7.2 times more rapid than in mice and dogs, respectively, and its blood level in rats is low. Moreover, the biological half-life of oxaprozin is 39 to 43 hr and 49 to 69 hr in dogs and humans, respectively. From these results, it is suggested that oxaprozin is more potent than ibuprofen, phenylbutazone and aspirin, and in clinical use, it is a long acting anti-inflammatory drug.

Analgesics↗